Literature DB >> 1311378

Treatment of aggressive cytomegalovirus retinitis with ganciclovir in combination with foscarnet in a child infected with human immunodeficiency virus.

K M Butler1, M D De Smet, R N Husson, B Mueller, K Manjunath, K Montrella, G Lovato, P Jarosinski, R B Nussenblatt, P A Pizzo.   

Abstract

Ganciclovir and foscarnet are both effective for cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome, but the benefits of either agent given alone are limited. A child infected with human immunodeficiency virus who had cytomegalovirus retinitis that progressed despite treatment with either agent alone received the combination of ganciclovir and foscarnet. This treatment resulted in a sustained clinical response.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1311378     DOI: 10.1016/s0022-3476(05)80926-6

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  10 in total

1.  Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

Review 2.  Pediatric human immunodeficiency virus infection.

Authors:  J B Domachowske
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

3.  Rapid screening for resistance to ganciclovir and foscarnet of primary isolates of human cytomegalovirus from culture-positive blood samples.

Authors:  G Gerna; A Sarasini; E Percivalle; M Zavattoni; F Baldanti; M G Revello
Journal:  J Clin Microbiol       Date:  1995-03       Impact factor: 5.948

4.  Cytomegalovirus infection after intestinal transplantation in children.

Authors:  J Bueno; M Green; S Kocoshis; H Furukawa; K Abu-Elmagd; E Yunis; W Irish; S Todo; J Reyes; T E Starzl
Journal:  Clin Infect Dis       Date:  1997-11       Impact factor: 9.079

5.  The spectrum of eye disease in children with AIDS due to vertically transmitted HIV disease: clinical findings, virology and recommendations for surveillance.

Authors:  C J Hammond; J A Evans; S M Shah; J F Acheson; M D Walters
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-03       Impact factor: 3.117

6.  The role of ganciclovir for the management of cytomegalovirus retinitis in HIV patients: Pharmacological review and update on new developments.

Authors:  A Tseng; M Foisy
Journal:  Can J Infect Dis       Date:  1996-05

7.  Combined ganciclovir and foscarnet in pediatric cytomegalovirus retinitis.

Authors:  S M Sastry; C H Epps; R C Walton; S N Rana; R J Sanders
Journal:  J Natl Med Assoc       Date:  1996-10       Impact factor: 1.798

8.  Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  Lynne M Mofenson; Michael T Brady; Susie P Danner; Kenneth L Dominguez; Rohan Hazra; Edward Handelsman; Peter Havens; Steve Nesheim; Jennifer S Read; Leslie Serchuck; Russell Van Dyke
Journal:  MMWR Recomm Rep       Date:  2009-09-04

Review 9.  Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections.

Authors:  A J Wagstaff; H M Bryson
Journal:  Drugs       Date:  1994-08       Impact factor: 9.546

Review 10.  Ganciclovir. An update of its therapeutic use in cytomegalovirus infection.

Authors:  A Markham; D Faulds
Journal:  Drugs       Date:  1994-09       Impact factor: 9.546

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.